Ondansetron 0.8 MG/ML Oral Solution — RxCUI 312085
RxNorm drug concept · Semantic clinical drug
RxCUI 312085
Semantic clinical drug · SCD
● Current RxNorm concept 15 FDA products
27 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI312085
Official nameOndansetron 0.8 MG/ML Oral Solution
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asondansetron 4 MG per 5 ML Oral Solution; ondansetron HCl 4 MG in 5 mL Oral Solution; ondansetron (as ondansetron HCl dihydrate) 4 MG per 5 ML Oral Solution
FDA products mapped15
Package NDCs mapped27
Reported Medicaid activity (SDUD)592,968 prescriptions · 50 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Ondansetron: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Not at all. Ondansetron is approved to prevent nausea and vomiting from cancer chemotherapy, radiation therapy to the abdomen or whole body, and surgery. So you might receive it be...
- What exactly is ondansetron used for — is it just for chemo patients?
- The regular tablet is swallowed like any other pill. The orally disintegrating tablet (ODT) is placed on your tongue and allowed to dissolve — don't chew or swallow it whole. For c...
- How do I take the tablet or the dissolving tablet correctly?
🕸️ Concept Web — How Ondansetron 0.8 MG/ML Oral Solution Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Ondansetron 0.8 MG/ML Oral Solution
RxCUI 312085 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Ondansetron
26225IN
-
Ondansetron
-
Dose forms 6
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Ondansetron Oral Solution
373146SCDF -
Ondansetron Oral Liquid Product
1161032SCDG -
Ondansetron Oral Product
1161033SCDG -
Oral Solution
316968DF -
Oral Liquid Product
1151137DFG -
Oral Product
1151131DFG
-
Ondansetron Oral Solution
-
Clinical & branded drugs 1
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Ondansetron 0.8 MG/ML
330073SCDC
-
Ondansetron 0.8 MG/ML
Showing up to 8 concepts per family — 8 of 8 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Ondansetron 0.8 MG/ML
SCDC · 330073 -
Ondansetron Oral Solution
SCDF · 373146 -
Ondansetron Oral Liquid Product
SCDG · 1161032 -
Ondansetron Oral Product
SCDG · 1161033
📦 FDA Products & Package NDCs
15 products · 27 package NDCs
27 package NDCs map to RxCUI 312085 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00054-0064-47 | 1 BOTTLE, GLASS in 1 CARTON (0054-0064-47) / 50 mL in 1 BOT... | Ondansetron Hydrochloride | Hikma Pharmaceuticals USA Inc. | 2006-12-26 |
| 00121-0882-51 | 50 mL in 1 BOTTLE, PLASTIC (0121-0882-51) | Ondansetron | PAI Holdings, LLC dba PAI Pharma | 2026-04-20 |
| 00121-4882-94 | 3 TRAY in 1 CASE (0121-4882-94) / 10 CUP in 1 TRAY / 5 mL i... | Ondansetron | PAI Holdings, LLC dba PAI Pharma | 2026-06-09 |
| 16714-0671-02 | 1 BOTTLE, PLASTIC in 1 CARTON (16714-671-02) / 50 mL in 1 B... | Ondansetron | NorthStar Rx LLC | 2007-11-28 |
| 17856-0672-01 | 60 SYRINGE in 1 CASE (17856-0672-1) / 2.5 mL in 1 SYRINGE | Ondansetron | Atlantic Biologics Corp. | 2025-10-23 |
| 17856-0672-02 | 120 SYRINGE in 1 CASE (17856-0672-2) / 2.5 mL in 1 SYRINGE | Ondansetron | Atlantic Biologics Corp. | 2025-10-23 |
| 17856-0672-03 | 120 SYRINGE in 1 CASE (17856-0672-3) / 2.5 mL in 1 SYRINGE | Ondansetron | Atlantic Biologics Corp. | 2025-10-23 |
| 17856-0672-04 | 72 CUP, UNIT-DOSE in 1 CASE (17856-0672-4) / 5 mL in 1 CUP,... | Ondansetron | Atlantic Biologics Corp. | 2025-10-23 |
| 17856-0691-01 | 1.5 mL in 1 SYRINGE (17856-0691-1) | Ondansetron | ATLANTIC BIOLOGICALS CORP. | 2024-04-17 |
| 17856-0691-02 | 2.5 mL in 1 SYRINGE, PLASTIC (17856-0691-2) | Ondansetron | ATLANTIC BIOLOGICALS CORP. | 2024-04-17 |
| 17856-0691-04 | 2.5 mL in 1 SYRINGE, PLASTIC (17856-0691-4) | Ondansetron | ATLANTIC BIOLOGICALS CORP. | 2024-04-17 |
| 17856-0691-05 | 5 mL in 1 CUP (17856-0691-5) | Ondansetron | ATLANTIC BIOLOGICALS CORP. | 2024-04-17 |
| 17856-0691-06 | 120 SYRINGE in 1 BOX, UNIT-DOSE (17856-0691-6) / 1.25 mL in... | Ondansetron | ATLANTIC BIOLOGICALS CORP. | 2024-04-17 |
| 17856-0691-07 | 48 SYRINGE in 1 BOX, UNIT-DOSE (17856-0691-7) / 1.9 mL in 1... | Ondansetron | ATLANTIC BIOLOGICALS CORP. | 2024-04-17 |
| 17856-0691-08 | 60 SYRINGE in 1 BOX, UNIT-DOSE (17856-0691-8) / 2.5 mL in 1... | Ondansetron | ATLANTIC BIOLOGICALS CORP. | 2024-04-17 |
| 50268-0647-14 | 40 CUP, UNIT-DOSE in 1 TRAY (50268-647-14) / 5 mL in 1 CUP,... | Ondansetron | AvPAK | 2023-09-20 |
| 51672-4091-03 | 1 BOTTLE in 1 CARTON (51672-4091-3) / 50 mL in 1 BOTTLE | Ondansetron | Taro Pharmaceuticals U.S.A., Inc. | 2007-11-30 |
| 60687-0252-86 | 3 TRAY in 1 CASE (60687-252-86) / 10 CUP, UNIT-DOSE in 1 TR... | Ondansetron | American Health Packaging | 2019-02-05 |
| 62135-0555-24 | 2 TRAY in 1 BOX (62135-555-24) / 10 PACKAGE in 1 TRAY / 5 m... | Ondansetron Hydrochloride | Chartwell RX, LLC. | 2024-05-28 |
| 62135-0555-58 | 50 mL in 1 BOTTLE (62135-555-58) | Ondansetron Hydrochloride | Chartwell RX, LLC. | 2022-10-04 |
| 65162-0691-19 | 10 CUP, UNIT-DOSE in 1 TRAY (65162-691-19) / 5 mL in 1 CUP,... | Ondansetron | Amneal Pharmaceuticals LLC | 2010-12-17 |
| 65162-0691-79 | 50 mL in 1 BOTTLE (65162-691-79) | Ondansetron | Amneal Pharmaceuticals LLC | 2010-12-17 |
| 65862-0208-04 | 1 BOTTLE, PLASTIC in 1 CARTON (65862-208-04) / 50 mL in 1 B... | Ondansetron | Aurobindo Pharma Limited | 2007-11-28 |
| 65862-0208-50 | 1 BOTTLE in 1 CARTON (65862-208-50) / 50 mL in 1 BOTTLE | Ondansetron | Aurobindo Pharma Limited | 2007-11-28 |
| 68071-3611-05 | 1 BOTTLE, PLASTIC in 1 CARTON (68071-3611-5) / 50 mL in 1 B... | Ondansetron | NuCare Pharmaceuticals,Inc. | 2024-06-19 |
| 68094-0763-62 | 3 TRAY in 1 CASE (68094-763-62) / 10 CUP, UNIT-DOSE in 1 TR... | Ondansetron Hydrochloride | Precision Dose Inc. | 2015-02-27 |
| 68999-0555-24 | 2 TRAY in 1 BOX (68999-555-24) / 10 CUP, UNIT-DOSE in 1 TRA... | Ondansetron Hydrochloride | Chartwell Governmental & Specialty RX, LLC. | 2026-01-06 |
Observed labelers:
ATLANTIC BIOLOGICALS CORP. (7) ·
Atlantic Biologics Corp. (4) ·
Amneal Pharmaceuticals LLC (2) ·
Aurobindo Pharma Limited (2) ·
Chartwell RX, LLC. (2) ·
PAI Holdings, LLC dba PAI Pharma (2)
· +8 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
💲 Pricing (NADAC)
NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ml · median
$0.2891
Range $0.2891–$0.2891
· middle 50% $0.2891–$0.2891
· 5 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.
🧾 Billing Codes (HCPCS)
Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
| Code | Descriptor | Mapped packages | Sources |
|---|---|---|---|
| Q0162 | Ondansetron oral | 5 | CMS |
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.